Biopharmaceutics classification evaluation for paris saponin VII

Area of Science:

• Pharmacology
• Biopharmaceutics
• Drug Discovery

Background:

• Paris saponin VII (PSVII) is a compound with potential therapeutic applications.
• Understanding its biopharmaceutics is crucial for predicting its in vivo behavior and optimizing drug delivery.

Purpose of the Study:

• To comprehensively evaluate the biopharmaceutic characteristics of paris saponin VII (PSVII).
• To determine the solubility, permeability, and intestinal absorption of PSVII.
• To investigate the role of efflux transporters in PSVII transport.

Main Methods:

• Equilibrium solubility measurements in various solvents and pH conditions.
• Oil/water partition coefficient (lgP_app) and Caco-2 cell monolayer model for apparent permeability coefficient (PC_app) determination.
• Investigation of p-glycoprotein and multidrug resistance-related protein 2 effects on PSVII transport.
• In vivo study of PSVII small intestinal absorption in rats.

Main Results:

• PSVII demonstrated very low equilibrium solubility across different pH values (dose number > 1).
• The compound exhibited low lipophilicity (lgP_app < 0) and low apparent permeability (PC_app(AP-BL) < 14.96 × 10^-6 cm·s^-1) in Caco-2 cells.
• PSVII transport was not influenced by p-glycoprotein or multidrug resistance-related protein 2 inhibitors, and it was not detected in rat small intestinal mucosa after oral administration.

Conclusions:

• PSVII possesses poor solubility and permeability, classifying it as a Biopharmaceutics Classification System (BCS) Class IV compound.
• These characteristics suggest a significant limitation of low oral bioavailability for PSVII in clinical settings.
• Further formulation strategies may be required to enhance the oral delivery and efficacy of PSVII.